A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant

Trial Profile

A Phase 1b/2 Study of Safety and Efficacy of MLN0128 (Dual TORC1/2 Inhibitor) in Combination With Exemestane or Fulvestrant Therapy in Postmenopausal Women With ER+/HER2- Advanced or Metastatic Breast Cancer That Has Progressed on Treatment With Everolimus in Combination With Exemestane or Fulvestrant

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Aug 2017

At a glance

  • Drugs Sapanisertib (Primary) ; Exemestane; Fulvestrant
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 08 Aug 2017 Planned End Date changed from 12 Nov 2017 to 16 Mar 2018.
    • 08 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 31 Jan 2018.
    • 20 Apr 2017 Planned End Date changed from 1 Nov 2017 to 12 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top